trelegy ellipta for asthma - Yahoo Search Results

Ads
related to: trelegy ellipta for asthma
YUPELRI® (revefenacin) - Inhalation Solution

www.yupelri.com
To Learn More About YUPELRI, Visit The Website Or Ask Your Doctor Today! Ask Your Doctor About YUPELRI Or Visit The Website For More Information.
Sign Up
Sign Up To Stay Informed

Register To Receive News & Updates

Access and Coverage
See Insurance And

Coverage Information

Resources
Useful Information

And Materials

Learn More
Quick Facts

About COPD
Yupelri® (revefenacin) - Inhalation Solution

www.yupelrihcp.com
Discover a Rx Option That Can Help Your Patients Manage Their Condition. Official HCP Website: Learn More About Yupelri® As A Treatment Option For Your Patients.
To Administer
Review the Efficacy
See Savings Card
Important Safety Info

Search results

- A Life-long Asthma Patient Shares How She’s Learned to Manage Her Condition
  Parade via Yahoo News· 11 months ago
  Rashelle Stocker was diagnosed with asthma in third grade after having her first attack on the...
- These Inhalers No Longer Cost More Than $35 Per Month
  Verywell Health via Yahoo News· 3 weeks ago
  Grace Cary / Getty Images Fact checked by Nick Blackmer Key Takeaways Three major pharmaceutical...
- Theravance Biopharma (TBPH) to Sell Trelegy Royalty Interests
  Zacks via Yahoo Finance· 2 years ago
  Theravance Biopharma (TBPH) agrees to sell its Trelegy royalty interests to Royalty Pharma. The...
- See price hikes for top 25 drugs covered by Medicare; NJ drugmakers sue to stop change
  App.com | Asbury Park Press via Yahoo Finance· 8 months ago
  Average prices for 25 widely used drugs covered by Medicare more than tripled since they were...
- GSK to cap out-of-pocket inhaler costs in US
  Reuters via Yahoo News· 4 weeks ago
  The cost cap would apply to all of its asthma and chronic obstructive pulmonary disease (COPD) medicines, including Advair Diskus, Advair HFA, and...
- GSK's Key Drugs to Drive Sales in a Sluggish Second Half
  Zacks via Yahoo Finance· 2 years ago
  GSK's specialty products like Dovato, Nucala, Trelegy Ellipta, Shingrix are driving sales, making up...
- Innoviva Inc (INVA) Reports Growth Amidst Challenges in Q4 and Full Year 2023 Financial Results
  GuruFocus.com via Yahoo Finance· 2 months ago
  Revenue: Innoviva Inc (NASDAQ:INVA) reported a 35% year-over-year increase in net product revenues...
- GSK Gears Up to Report Q4 Earnings: What's in the Cards?
  Zacks via Yahoo Finance· 1 year ago
  GSK plc. GSK will report fourth-quarter 2022 results on Feb 1, before the opening bell. In the last...
- GSK Follows Rivals, to Cap Out-of-Pocket Inhaler Cost in US
  Zacks via Yahoo Finance· 4 weeks ago
  GSK plc (GSK) plans to lower the prices of its entire inhaled respiratory products to $35 per month...
- GSK's New Drugs and Pipeline Hold the Key to Growth in 2023
  Zacks via Yahoo Finance· 1 year ago
  GSK's specialty products like Dovato, Nucala, Trelegy Ellipta and Shingrix are likely to drive...